New strategy for developing 'next-generation' malaria vaccines
3 Nov
2009, 1331 Hrs
Washington, Nov 3 Experts have suggested a novel strategy for developing 'next-generation' malaria vaccines that will help targeting the long-term goal of eliminating and eradicating the deadly mosquito-borne disease.
While trials are underway testing the efficacy if GlaxoSmithKline Biologicals' (GSK Bio) RTS, S malaria vaccine, experts linked to PATH Malaria Vaccine Initiative (MVI) have suggested new approaches.
While most malaria vaccine candidates use one or more components of the malaria parasite to elicit an immune response, another approach uses a weakened form of the whole parasite.
MVI is working with Sanaria Inc. to develop a novel vaccine candidate that uses this approach with Plasmodium falciparum. It is currently being tested in adult volunteers in the United States.
Like RTS,S, many of these studies are focused on the pre-erythrocytic approach. They aim to trigger the immune system to defend against the parasite as soon as it enters a person's bloodstream or infects liver cells.
This prevents the parasite from maturing and multiplying in the liver, reentering the bloodstream, and infecting red blood cells.
Another approach targets the malaria parasite when it is most destructive: at the blood stage, when the parasite replicates rapidly in red blood cells. Blood-stage vaccines are not expected to block all infection. Instead, they aim to decrease the number of parasites in the blood, reducing the severity of malaria.
The researchers are also looking for vaccine candidates that block the transmission of malaria from mosquitoes to humans.
Transmission-blocking vaccines attempt to interrupt the life cycle of the parasite by inducing antibodies that prevent the parasite from maturing in the mosquito after it bites a vaccinated person.
The researchers also aim to develop vaccines against P. vivax, the less severe but more widespread malaria parasite affecting humans.
MVI plans to intensify its support for vivax approaches in hopes of eventually combining them with vaccines targeting P. falciparum.
As the number of potential malaria vaccine candidates increases, scientists will need new and better technologies to assess their potential efficacy and decide which should go forward.
MVI is supporting the refinement and development of both laboratory tools and methodologies for evaluating vaccine candidates in humans. (ANI)
| Discuss this story on KhabarExpress Forum Pelagian Dictionary strategydeveloping next-generation malaria vaccin Comments to this News Be the first to comment on this News Post Your Comments to this News Posting Rules |
- As far as Kashmir issue is concerned, India will not redraw borders: Singh
- Pakistan has not done enough on the Mumbai terror attacks: Manmohan Singh
- No apprehension about US viewing India differently: Manmohan Singh
- Lucknow Zoo authorities treating tiger for cancer
- Winters leave Ladakh out of bound, make stocking of food material a must
- भारतीय क्रिकेट की मजबूत दीवार
- कंगारूओं के आगे ढेर, चीतों से कैसे मुकाबला करेंगें शेर
- Reducing greenhouse gases may not be enough to slow global warming
- बीकानेर महापौर चुनावः एक विश्लेषण
- Deepawali: The Festival Of Lights
Pantaloons Femina Miss India South 2010 Hyderabad Round Winners with Fashion Designer Prasad Bidappa
Katrina Cafe